Henry Skinner

Dr. Henry Skinner is CEO of the AMR Action Fund, a partnership that was set up by a coalition of pharmaceutical companies, philanthropies, and the European Investment Bank, with the support of the WHO, that aims to strengthen and accelerate antibiotic development.  Prior to joining the AMR Action Fund, Dr. Skinner was Senior Vice President, Venture at Tekla Capital Management, LLC, and served as Deputy Head and Managing Director of Novartis Venture Fund.  In addition, Dr. Skinner has been CEO of SelectX Pharmaceuticals and NeoGenesis Pharmaceuticals and has held positions in Business Development for Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn and Lexicon Genetics.  Dr. Skinner was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics, earned his Ph.D. in Microbiology and M.S. in Biochemistry from the University of Illinois and M.S. and B.S. in Biology/Biotechnology from Worcester Polytechnic Institute.